Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver

Metastatic Cancer Clinical Trial

Official title:

A Phase III, Multi-Center Controlled Trial With Stratified Randomization Comparing The Efficacy Of Interleukin-2 (IL-2) Plus Histamine Dihydrochloride (HDC) Versus IL-2 Alone To Increase The Duration Of Survival In Patients With AJCC Stage IV Malignant Melanoma With Hepatic Metastasis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00039234
• Other study ID #: CDR0000069365
• Secondary ID: MAXIM-MP-8899-01
• Status: Active, not recruiting
• Phase: Phase 3
• First received: June 6, 2002
• Last updated: December 17, 2013
• Start date: September 2002

Study information

• Verified date: December 2003
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Histamine dihydrochloride may help interleukin-2 kill more tumor cells by making tumor cells more sensitive to the drug. It is not yet known if interleukin-2 is more effective with or without histamine dihydrochloride in treating stage IV melanoma that is metastatic to the liver.

PURPOSE: Randomized phase III trial to compare the effectiveness of interleukin-2 with or without histamine dihydrochloride in treating patients who have stage IV melanoma that is metastatic to the liver.

Description:

OBJECTIVES:

• Compare the duration of survival in patients with stage IV melanoma with hepatic metastasis treated with interleukin-2 with or without histamine dihydrochloride.

• Compare the progression-free survival, response rate, response rate of hepatic tumors, and lack of disease progression in patients treated with these regimens.

• Determine the safety of these regimens, in terms of frequency, severity, and causal relationship of adverse events, in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center location (North America vs Europe), lactate dehydrogenase (less than ULN vs ULN or greater), and metastatic sites (liver only vs liver and other sites). Patients are randomized to one of two treatment arms.

• Arm I: Patients receive interleukin-2 (IL-2) subcutaneously (SC) twice daily on days 1 and 2 of weeks 1 and 3 and days 1-5 of weeks 2 and 4. Patients also receive histamine dihydrochloride SC over 10-30 minutes on days 1-5 of weeks 1-4.

• Arm II: Patients receive IL-2 as in arm I. In both arms, treatment repeats every 6 weeks for at least 8 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 3 years and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 224 patients (112 per treatment arm) will be accrued for this study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed stage IV melanoma

• Must have radiological evidence of lesions in liver (target or non-target)

• At least 1 measurable lesion outside previously irradiated field

• At least 20 mm by contrast-enhanced CT scan, MRI, medical photography, or physical exam OR at least 10 mm by spiral CT scan

• No prior or concurrent clinical and/or objective evidence of brain metastasis

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• WHO 0-1

Life expectancy:

• At least 3 months

Hematopoietic:

• Hemoglobin at least 9.5 g/dL

• WBC at least 3,000/mm^3

• Granulocyte count at least 2,000/mm^3

• Platelet count at least 100,000/mm^3

Hepatic:

• Bilirubin no greater than 2 times upper limit of normal (ULN)

• AST and ALT no greater than 4 times ULN

• Alkaline phosphatase no greater than 4 times ULN

• Hepatitis B and C negative

Renal:

• Creatinine no greater than 1.7 mg/dL

• Calcium no greater than 11.5 mg/dL

Cardiovascular:

• No abnormal thallium stress test

• No acute myocardial infarction within the past year

• No New York Heart Association class III or IV heart disease

Pulmonary:

• No asthma requiring active treatment within the past 5 years

• Oxygen saturation by pulse oximeter at least 90% unless FEV_1 is greater than 2 L or at least 75% predicted

Other:

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• HIV negative

• Concurrent medically-controlled (except with glyburide) or diet-controlled diabetes is allowed

• Concurrent medically-controlled thyroid dysfunction is allowed

• No other active malignancy within the past 5 years except carcinoma in situ of the cervix or localized squamous cell or basal cell skin cancer

• No serious non-malignant medical conditions, including psychiatric disability, that would preclude study compliance

• No active autoimmune disease (e.g., lupus, inflammatory bowel disease, or psoriasis)

• No active peptic and/or esophageal ulcer disease

• No hypersensitivity to histamine products or urticaria

• No active IV drug abuse

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No prior immunotherapy with high-dose IV interleukin-2 (IL-2)

• No prior combination immunotherapy with chemotherapy

• At least 1 year since prior low-dose adjuvant IL-2 as part of vaccine therapy or as therapy for stage II or III melanoma

Chemotherapy:

• See Biologic therapy

Endocrine therapy:

• No chronic systemic glucocorticoid steroids

• Asthma inhalers, topical creams, or intra-articular injections allowed

• Hormonal therapy for non-melanoma-related conditions allowed

Radiotherapy:

• See Disease Characteristics

• Concurrent radiotherapy as palliative therapy for isolated non-target lesions (e.g., bone lesions) allowed

Surgery:

• Not specified

Other:

• At least 4 weeks since prior therapy directed at malignancy

• At least 4 weeks since prior investigational medications or therapies

• At least 2 weeks since prior parenteral antioxidants and/or vitamins

• At least 2 weeks since prior antibiotics for active illness

• At least 2 weeks since prior H2 antagonists, beta-blockers, antihypertensives, antimalarials, antitrypanosomals, neuromuscular-blocking agents, tricyclic antidepressants, or alprazolam

• At least 24 hours since prior antihistamines

• No prior enrollment in any Maxim Pharmaceuticals investigational trials

• No concurrent anticonvulsant therapy for seizure disorder

• No other concurrent investigational drug

• No concurrent H2 antagonists, tricyclic antidepressants, alprazolam, beta- blockers, antihypertensives, antitrypanosomals, antimalarials, or monoamine oxidase inhibitors

• No concurrent inhibitors of diamine oxidase, monoamine oxidase, or histamine N-methyltransferase

• No concurrent antihistamines

Study Design

Allocation: Randomized, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Melanoma
• Melanoma (Skin)
• Metastatic Cancer
• Neoplasm Metastasis

Intervention

Biological:
• aldesleukin

Drug:
• histamine dihydrochloride

Locations

Country	Name	City	State
Canada	Cross Cancer Institute	Edmonton	Alberta
Canada	Centre Hospitalier Universitaire de Quebec	Quebec City	Quebec
Germany	Charite - Universitaetsmedizin Berlin	Berlin
Germany	Universitatsklinik - Saarland	Homburg/Saar
Germany	Kiel Universitatshautklinik	Kiel
Germany	Klinische Kooperationseinheit fur Dermatoonkologie (DFKZ)	Mannheim
Germany	Klinikum Rechts Der Isar/Technische Universitaet Muenchen	Munich
United Kingdom	Royal Marsden Hospital - Sutton	London	England
United States	University of Colorado Cancer Center at University of Colorado Health Sciences Center	Aurora	Colorado
United States	Comprehensive Cancer Center at Our Lady of Mercy Medical Center	Bronx	New York
United States	University of Chicago Cancer Research Center	Chicago	Illinois
United States	Ellis Fischel Cancer Center at University of Missouri - Columbia	Columbia	Missouri
United States	James Graham Brown Cancer Center at University of Louisville	Louisville	Kentucky
United States	Beth Israel Medical Center	New York	New York
United States	Memorial Sloan-Kettering Cancer Center	New York	New York
United States	Hillman Cancer Center at University of Pittsburgh Cancer Institute	Pittsburgh	Pennsylvania
United States	Melanoma Center of St. Louis, Missouri Baptist Medical Center	Saint Louis	Missouri
United States	John Wayne Cancer Institute at Saint John's Health Center	Santa Monica	California
United States	Moffitt Clinic at Tampa General Hospital	Tampa	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Maxim Pharmaceuticals	National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Canada,  Germany,  United Kingdom,